[Federal Register Volume 70, Number 182 (Wednesday, September 21, 2005)]
[Notices]
[Pages 55400-55401]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-18791]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Government-Owned Inventions: Availability for Licensing and 
Cooperative Research and Development Agreements (CRADAs)

AGENCY: Centers for Disease Control and Prevention, Technology Transfer 
Office, Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention named in this notice is owned by agencies of the 
United States Government and is available for licensing in the United 
States (U.S.) in accordance with 35 U.S.C. 207, and is available for 
cooperative research and development agreements (CRADAs) in accordance 
with 15 U.S.C. 3710a, to achieve expeditious commercialization of 
results of federally funded research and development. A U.S. non-
provisional patent application and a PCT application have been filed. 
National stage foreign patent applications claiming priority to the PCT 
application are expected to be filed within the appropriate deadlines 
to extend market coverage for U.S. companies and may also be available 
for licensing.

ADDRESSES: Licensing and CRADA information, and information related to 
the technology listed below, may be obtained by writing to Suzanne 
Seavello Shope, J.D., Technology Licensing and Marketing Scientist, 
Technology Transfer Office, Centers for Disease Control and Prevention 
(CDC), Mailstop K-79, 4770 Buford Highway, Atlanta, GA 30341, telephone 
(770) 488-8613; facsimile (770) 488-8615; or e-mail [email protected]. A 
signed Confidential Disclosure Agreement (available under Forms at 
http://www.cdc.gov/tto) will be required to receive copies of 
unpublished patent applications and other information.

Diagnostics

Development of Real-Time PCR Assay for Detection of Pneumococcal DNA 
and Diagnosis of Pneumococcal Disease

    The ability to diagnose pneumococcal pneumonia is limited by the 
lack of a sensitive, specific, and accurate laboratory assay. Using the 
PsaA (pneumococcal protein A) protein gene, CDC researchers have 
designed unique primers and probes and developed a real-time PCR assay 
for detection of pneumococcal DNA in serum and other sterile site body 
fluids for the diagnosis of pneumococcal disease. The PCR assay 
provides a tool for accurate diagnosis by clinicians, and for 
determination of the effectiveness (efficacy) of newly licensed 
pneumococcal polysaccharide-conjugate

[[Page 55401]]

vaccines or future common protein pneumococcal vaccines.
    Inventors: Maria da Gloria Carvalho, Jacquelyn S. Sampson, Edwin W. 
Ades, George Carlone and Karen McCaustland, CDC Ref. : I-001-
05.

    Dated: September 9, 2005.
James D. Seligman,
Associate Director for Program Services, Centers for Disease Control 
and Prevention.
[FR Doc. 05-18791 Filed 9-20-05; 8:45 am]
BILLING CODE 4163-18-P